MetaCap

Humacyte Inc. Company Profile

NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.4454-0.0971 (-17.90%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Humacyte at a glance

Humacyte Inc. (NASDAQ: HUMA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Durham, NC. Humacyte is led by Dr. Laura E. Niklason M.D., Ph.D. and employs about 184 people. The company's shares have traded publicly since 2020.

At a market capitalization of $123.7 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001818382, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Humacyte do?

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Business description based on the company's public filings.

Company information

Legal name
Humacyte Inc.
Ticker
NASDAQ: HUMA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Laura E. Niklason M.D., Ph.D.
Employees
184
Headquarters
2525 East North Carolina Highway 54, Durham, NC, United States
Phone
919 313 9633
IPO year
2020
Market cap
$123.73M
SEC CIK
0001818382
Latest annual report
10-K · Mar 27, 2026

Companies similar to Humacyte

HUMA peer companies
CompanyPrice% ChgMarket capCompare
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs HUMA
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs HUMA
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs HUMA
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs HUMA
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs HUMA
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs HUMA
TARAProtara Therapeutics Inc.2.28-5.00%$140.38Mvs HUMA
STROSutro Biopharma Inc.8.60-1.38%$142.77Mvs HUMA

Related